RGNXHealthcare · BiotechnologyThe 11 Wall Street analysts covering REGENXBIO, Inc. hold a median 12-month price target of $19 — +122.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 12 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores REGENXBIO, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (71): The share count has been shrinking and the company is not leaning on new borrowing.
Volatility (21): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RGNX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +122.7% from it.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Aug 2026 | Baird | Maintains | Outperform | $32 → $29 |
| 25 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $23 → $21 |
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $26 → $23 |
| 7 Aug 2026 | Barclays | Downgrade | Equal-Weight | — |
| 7 Aug 2026 | Barclays | Downgrade | Equal-Weight | $12 |
| 24 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $26 |
| 22 June 2026 | Baird | Maintains | Outperform | $27 → $32 |
| 22 June 2026 | Baird | Maintains | Outperform | — |
| 22 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 22 June 2026 | Leerink Partners | Maintains | Outperform | $17 → $18 |
| 5 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2026 | B of A Securities | Maintains | Buy | — |
| 15 May 2026 | Barclays | Maintains | Overweight | — |
| 9 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Mar 2026 | Morgan Stanley | Maintains | Overweight | — |
| 10 Feb 2026 | Chardan Capital | Maintains | Buy | — |
| 10 Feb 2026 | Goldman Sachs | Maintains | Neutral | — |
| 10 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RGNX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, REGENXBIO, Inc. returned −10.1% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 39% of US stocks
Cheaper than 15% of US stocks
Cheaper than 78% of US stocks
Higher than 98% of US stocks
Higher than 94% of US stocks
Higher than 99% of US stocks
Higher than 85% of US stocks
Higher than 5% of US stocks
Higher than 10% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
REGENXBIO, Inc. has a market value of $563.1M and an enterprise value of $708.0M.
Revenue in the twelve months to 30 June 2026: $174.5M. The latest quarter grew 405.7% year on year.
Net income over the same four quarters: −$196.4M, a −112.6% net margin.
Diluted earnings per share, trailing twelve months: $−3.79.
Free cash flow in the twelve months to 30 June 2026: −$249.7M.
Trailing P/E: −2.3×; forward P/E: −2.8× — the forward figure prices analyst consensus estimates, not reported earnings.
REGENXBIO, Inc. employs 371 people — $470K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own REGENXBIO, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
REGENXBIO announced it will participate in the Baird 2026 Global Healthcare Conference, featuring a fireside chat on Tuesday, September 15 at 8:30 a.m. The company disclosed the event in a press release dated September 8, 2026.
Why it matters — Conference participation gives investors an opportunity to hear REGENXBIO's management discuss the company and its pipeline directly.
REGENXBIO's stock fell 25% after the FDA placed a clinical hold on its gene therapy RGX-121, which is being developed for MPS II. The hold followed asymptomatic spine MRI findings in five trial participants.
Why it matters — RGNX watchers would care because a clinical hold on a key pipeline candidate could delay development of RGX-121 and weigh on the company's outlook.
Regenxbio faces a clinical hold on RGX-121 for Hunter Syndrome, which complicates milestone payments and royalty streams, though the company maintains a sufficient cash runway into Q4 2027. Pivotal data for its AbbVie-partnered eye disease program and a BLA submission for RGX-202 in DMD are slated as near-term catalysts.
Why it matters — RGNX watchers would care because the RGX-121 clinical hold and upcoming binary catalysts are significant developments that could materially affect the company's regulatory and financial outlook.
REGENXBIO announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. The appointment was announced by the company on that date.
Why it matters — Adding a new board member reflects a change in REGENXBIO's corporate governance and leadership oversight, which shareholders and industry watchers may track.
Johnson Fistel, PLLP is investigating REGENXBIO Inc. on behalf of investors who suffered losses, and is examining whether those losses may be recoverable under federal securities laws. The investigation follows a clinical hold involving the company.
Why it matters — The investigation following a clinical hold signals potential investor-loss concerns tied to REGENXBIO's product development setbacks, which may be of interest to those tracking the company.
The 11 Wall Street analysts covering REGENXBIO, Inc. have a median 12-month price target of $19, with estimates ranging from $10 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering REGENXBIO, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks REGENXBIO, Inc. 53 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, REGENXBIO, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (71 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +122.7% from the last close, and Ticker Nerd's factor model ranks REGENXBIO, Inc. 53 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering REGENXBIO, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RGNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $50 over the next 12 months.
REGENXBIO, Inc. returned -10.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapy.
The most recent item we track (PRNewsWire, 8 Sept 2026): "REGENXBIO to Participate in Upcoming Investor Conferences". REGENXBIO announced it will participate in the Baird 2026 Global Healthcare Conference, featuring a fireside chat on Tuesday, September 15 at 8:30 a.m. The company disclosed the event in a press release dated September 8, 2026.
REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapy. REGENXBIO Inc. develops and commercializes recombinant adeno-associated virus (AAV)–based treatments designed to deliver functional genes to cells and address genetic defects. Its current work centers on therapeutic programs in retinal, metabolic, and neurodegenerative diseases, supported by its proprietary NAV Technology Platform. The company also licenses its AAV gene-delivery technology to other biotechnology partners, combining internal drug development with platform licensing. REGENXBIO Inc. plays a specialized role in the biotechnology market by advancing gene therapy candidates and enabling broader use of AAV-based delivery systems across the life sciences industry.
CEO Mr. Curran M. Simpson M.S. · 371 employees · United States · https://www.regenxbio.com
